KR20240100778A - Food manufacturing method to improve sarcopenia caused by infection with COVID-19 or as a side effect of vaccination - Google Patents
Food manufacturing method to improve sarcopenia caused by infection with COVID-19 or as a side effect of vaccination Download PDFInfo
- Publication number
- KR20240100778A KR20240100778A KR1020220182757A KR20220182757A KR20240100778A KR 20240100778 A KR20240100778 A KR 20240100778A KR 1020220182757 A KR1020220182757 A KR 1020220182757A KR 20220182757 A KR20220182757 A KR 20220182757A KR 20240100778 A KR20240100778 A KR 20240100778A
- Authority
- KR
- South Korea
- Prior art keywords
- powder
- food ingredients
- food
- mixture
- mixed
- Prior art date
Links
- 208000001076 sarcopenia Diseases 0.000 title claims abstract description 43
- 235000013305 food Nutrition 0.000 title claims abstract description 25
- 230000000694 effects Effects 0.000 title claims abstract description 24
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 21
- 208000025721 COVID-19 Diseases 0.000 title claims abstract description 20
- 238000002255 vaccination Methods 0.000 title claims abstract description 18
- 208000015181 infectious disease Diseases 0.000 title description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 62
- 235000012041 food component Nutrition 0.000 claims abstract description 46
- 239000005417 food ingredient Substances 0.000 claims abstract description 46
- 210000003205 muscle Anatomy 0.000 claims abstract description 36
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 31
- 239000004310 lactic acid Substances 0.000 claims abstract description 31
- 241000894006 Bacteria Species 0.000 claims abstract description 25
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 22
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 22
- 238000002156 mixing Methods 0.000 claims abstract description 15
- 238000005728 strengthening Methods 0.000 claims abstract description 11
- 102000004190 Enzymes Human genes 0.000 claims abstract description 7
- 108090000790 Enzymes Proteins 0.000 claims abstract description 7
- 150000001413 amino acids Chemical class 0.000 claims abstract description 7
- 238000000855 fermentation Methods 0.000 claims abstract description 6
- 239000000126 substance Substances 0.000 claims abstract description 6
- 235000000346 sugar Nutrition 0.000 claims abstract description 6
- 150000008163 sugars Chemical class 0.000 claims abstract description 5
- 239000000843 powder Substances 0.000 claims description 70
- 239000000203 mixture Substances 0.000 claims description 27
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 20
- 235000013351 cheese Nutrition 0.000 claims description 16
- 235000013601 eggs Nutrition 0.000 claims description 16
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims description 15
- 241001454694 Clupeiformes Species 0.000 claims description 15
- 235000019513 anchovy Nutrition 0.000 claims description 15
- 235000010469 Glycine max Nutrition 0.000 claims description 13
- 244000068988 Glycine max Species 0.000 claims description 13
- 235000013336 milk Nutrition 0.000 claims description 12
- 239000008267 milk Substances 0.000 claims description 12
- 210000004080 milk Anatomy 0.000 claims description 12
- 235000013618 yogurt Nutrition 0.000 claims description 11
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 10
- 229930003268 Vitamin C Natural products 0.000 claims description 10
- 235000019154 vitamin C Nutrition 0.000 claims description 10
- 239000011718 vitamin C Substances 0.000 claims description 10
- 229930003316 Vitamin D Natural products 0.000 claims description 9
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 9
- 108010046377 Whey Proteins Proteins 0.000 claims description 9
- 102000007544 Whey Proteins Human genes 0.000 claims description 9
- 235000019166 vitamin D Nutrition 0.000 claims description 9
- 239000011710 vitamin D Substances 0.000 claims description 9
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 9
- 229940046008 vitamin d Drugs 0.000 claims description 9
- 235000013322 soy milk Nutrition 0.000 claims description 8
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 7
- 229910052791 calcium Inorganic materials 0.000 claims description 7
- 239000011575 calcium Substances 0.000 claims description 7
- 235000001465 calcium Nutrition 0.000 claims description 7
- 235000021109 kimchi Nutrition 0.000 claims description 7
- 235000007119 Ananas comosus Nutrition 0.000 claims description 6
- 235000014443 Pyrus communis Nutrition 0.000 claims description 6
- 240000001987 Pyrus communis Species 0.000 claims description 6
- 244000099147 Ananas comosus Species 0.000 claims description 5
- 239000005862 Whey Substances 0.000 claims description 5
- 235000011511 Diospyros Nutrition 0.000 claims description 4
- 244000236655 Diospyros kaki Species 0.000 claims description 4
- 238000010521 absorption reaction Methods 0.000 claims description 4
- 230000029087 digestion Effects 0.000 claims description 4
- 238000000354 decomposition reaction Methods 0.000 claims description 3
- 229940088598 enzyme Drugs 0.000 abstract description 6
- 238000000034 method Methods 0.000 abstract description 5
- 235000015097 nutrients Nutrition 0.000 abstract description 5
- 102000035195 Peptidases Human genes 0.000 abstract description 4
- 108091005804 Peptidases Proteins 0.000 abstract description 4
- 235000021075 protein intake Nutrition 0.000 abstract description 3
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 27
- 235000018102 proteins Nutrition 0.000 description 16
- 241001678559 COVID-19 virus Species 0.000 description 7
- 229940022005 RNA vaccine Drugs 0.000 description 6
- 108700021021 mRNA Vaccine Proteins 0.000 description 6
- 210000003470 mitochondria Anatomy 0.000 description 6
- 230000006378 damage Effects 0.000 description 4
- 239000003531 protein hydrolysate Substances 0.000 description 4
- 235000021119 whey protein Nutrition 0.000 description 4
- 206010028289 Muscle atrophy Diseases 0.000 description 3
- 229940096437 Protein S Drugs 0.000 description 3
- 101710198474 Spike protein Proteins 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000020763 muscle atrophy Effects 0.000 description 3
- 201000000585 muscular atrophy Diseases 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000001087 myotubule Anatomy 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 244000298697 Actinidia deliciosa Species 0.000 description 1
- 235000009436 Actinidia deliciosa Nutrition 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 241000234671 Ananas Species 0.000 description 1
- 102000053723 Angiotensin-converting enzyme 2 Human genes 0.000 description 1
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 240000000599 Lentinula edodes Species 0.000 description 1
- 208000034819 Mobility Limitation Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000008425 Protein deficiency Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010047626 Vitamin D Deficiency Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 210000003314 quadriceps muscle Anatomy 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L11/00—Pulses, i.e. fruits of leguminous plants, for production of food; Products from legumes; Preparation or treatment thereof
- A23L11/60—Drinks from legumes, e.g. lupine drinks
- A23L11/65—Soy drinks
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L15/00—Egg products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L17/00—Food-from-the-sea products; Fish products; Fish meal; Fish-egg substitutes; Preparation or treatment thereof
- A23L17/10—Fish meal or powder; Granules, agglomerates or flakes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/06—Enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A23L33/155—Vitamins A or D
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/316—Foods, ingredients or supplements having a functional effect on health having an effect on regeneration or building of ligaments or muscles
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Food Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Agronomy & Crop Science (AREA)
- Botany (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
본 발명은 COVID-19의 감염 또는 백신접종의 부작용 후유증으로 발생하는 근감소증을 개선하는 식품제조방법에 관한 것으로서,
근(筋)감소의 저지(沮止)와 개선(改善)을 도모(圖謀)하고. 근력(筋力)의 유지(維持)와 강화(强化)를 시도(試圖)하는 것이 그 치료특징인 치료메카니즘에 의거하여. 그에 적합한 근(筋)감소의 저지(沮止)와 개선(改選)을 목적으로 하는 단백질들이 풍부한 식품재료들과, 근력(筋力)의 유지(維持)와 강화(强化)을 목적으로 하는 영양소가 풍부한 식품재료들을 혼합하여 상기(上記)한 식품재료들을 함유(含有)한 혼합(混合)식품재료를 제조하되 일일(一日)단백질 섭취량(攝取量)과 영양소의 양(量)를 임의 조절 가능하도록 하게 할 목적으로 하는 상기한 식품재료들을 함유(含有)한 혼합식품재료를 제조하고, 그 후 동(同)혼합식품재료를 먹기와 소화흡수를 용이하게 할 목적으로 하는 단백질천연분해효소(:단백질을 아미노산들로 분해하는 천연효소)와 및 혼합유산균들(; 당을 젖산과 기타 발효(醱酵)후(後)물질을 생산하는 여러 종류의 유산균의 혼합균주)로 발효하여 제조하는 것이 그 특징인 근감소증을 개선하는 식품제조법에 관한 것이다.
유산소운동과 본 발명의 제조법으로 제조한 식품의 섭취를 병행하면, COVID-19의 감염 또는 백신접종의 부작용 후유증으로 발생하는 근감소증이 저지되고 개선되는 효과가 있다.The present invention relates to a food manufacturing method that improves sarcopenia that occurs as a side effect of COVID-19 infection or vaccination,
To prevent and improve muscle loss. Based on the treatment mechanism, the characteristic of the treatment is to attempt to maintain and strengthen muscle strength. Food ingredients rich in protein for the purpose of preventing and improving muscle loss, and nutrients for maintaining and strengthening muscle strength are included. By mixing abundant food ingredients, mixed food ingredients containing the above-mentioned food ingredients are manufactured, but the daily protein intake and amount of nutrients can be arbitrarily adjusted. To manufacture mixed food ingredients containing the above-mentioned food ingredients for the purpose of making it easier to eat, digest and absorb the mixed food ingredients, and then to use natural proteolytic enzymes (: It is manufactured by fermenting with natural enzymes that break down proteins into amino acids) and mixed lactic acid bacteria (a mixed strain of various types of lactic acid bacteria that produce sugars and produce lactic acid and other post-fermentation substances). It is about a food manufacturing method that improves the characteristic sarcopenia.
Combining aerobic exercise with the consumption of food prepared by the method of the present invention has the effect of preventing and improving sarcopenia that occurs as a side effect of COVID-19 infection or vaccination.
Description
본 발명은 SARS-CoV-2 바이러스(코로나19 바이러스; 'COVID-19' 라고 한다)의 감염의 또는 백신접종의 부작용 후유증으로 발생하는 근감소증을 개선하는 식품제조방법에 관한 것으로, The present invention relates to a food manufacturing method that improves sarcopenia that occurs as a side effect of infection or vaccination with the SARS-CoV-2 virus (COVID-19 virus; referred to as 'COVID-19'),
근(筋)감소의 저지(沮止)와 개선(改善)을 도모(圖謀)하고. 근력(筋力)의 유지(維持)와 강화(强化)를 시도(試圖)하는 것이 그 치료특징인 치료메카니즘에 의거. 그에 적용가능한 근(筋)감소의 저지(沮止)와 개선(改選)을 목적으로 하는 단백질들이 풍부한 식품재료들과, 근력(筋力)의 유지(維持)와 강화(强化)을 목적으로 하는 영양소가 풍부한 식품재료들을 혼합하여 상기(上記)한 식품재료들을 함유(含有)한 혼합(混合)식품재료를 제조하되 일일(一日)단백질 섭취량(攝取量)과 영양소의 양(量)를 임의 조절 가능하도록 하게 할 목적으로 하는 상기한 식품재료들을 함유(含有)한 혼합식품재료를 제조하고, 그 후 동(同)혼합식품재료를 먹기와 소화흡수를 용이하게 할 목적으로 하는 단백질천연분해효소(:단백질을 아미노산들로 분해하는 천연효소)와 및 혼합유산균들(; 당을 젖산과 기타 발효(醱酵)후(後)물질을 생산하는 여러 종류의 유산균의 혼합균주)로 발효하여 제조하는 것이 그 특징인 근감소증을 개선하는 식품제조법에 관한 것이다. To prevent and improve muscle loss. Based on the treatment mechanism, which is a characteristic of the treatment, it attempts to maintain and strengthen muscle strength . Applicable food ingredients rich in protein for the purpose of preventing and improving muscle loss , and nutrients for maintaining and strengthening muscle strength Mix food ingredients rich in food to produce mixed food ingredients containing the above-mentioned food ingredients, but arbitrarily control the daily protein intake and amount of nutrients. Manufacturing a mixed food material containing the above-mentioned food ingredients for the purpose of making it possible , and then producing a natural proteolytic enzyme (protein decomposition enzyme ) for the purpose of facilitating eating and digestion and absorption of the mixed food ingredients. It is manufactured by fermenting with natural enzymes that break down proteins into amino acids) and mixed lactic acid bacteria (mixtures of various types of lactic acid bacteria that produce sugars and produce lactic acid and other post-fermentation substances). It is about a food manufacturing method that improves the characteristic sarcopenia .
노화로 인해 발생하는 근감소증은 서서히 진행되지만, COVID-19의 감염의 또는 백신접종의 부작용 후유증으로 인해 발생하는 근감소증은 갑자기 급속히 진행된다. Sarcopenia that occurs due to aging progresses slowly, but sarcopenia that occurs due to side effects of COVID-19 infection or vaccination suddenly progresses rapidly.
COVID-19의 감염 또는 백신접종의 부작용 후유증으로 인해 발생하는 근감소증은 갑자기 급속히 진행되는 데, 보통은 지속적인 전신의 관절통과 근육통을 동반한 당뇨병의 발생으로부터 시작하여, 그 후 1- 1.5개월내에 체중(體重)이 10-15% 감소하며, 이 같은 체중의 격감(激減) 이후(後) 거의 동시에 갑자기 지속적으로 격심한 통증이 발생하고 있는 어깨 쪽 팔의 힘이 빠져서 커피잔을 들 수 없을 정도가 되며, 그 후 7-14일 전후하여 갑자기 보행 속도가 현저히 감소되고, 또 다리에 힘이 빠져서 계단을 걸어 올라가는 것이 아주 힘들어 지며, 결국은 앉았던 의자에서 기립하는 것 자체가 거의 불가능하게 된다. Sarcopenia, which occurs as a side effect of COVID-19 infection or vaccination, progresses suddenly and rapidly. It usually starts with the development of diabetes accompanied by persistent joint pain and muscle pain throughout the body , followed by weight loss within 1-1.5 months. Body weight decreases by 10-15% , and almost immediately after this drastic loss of body weight , the arm near the shoulder, where severe and persistent pain occurs, suddenly loses strength to the point where it is impossible to hold a coffee cup. Then , about 7 to 14 days later , walking speed suddenly decreases significantly, legs lose strength, making it very difficult to walk up stairs, and eventually, standing up from a chair becomes almost impossible.
노화로 인해 발생하는 근감소증의 치료제가 아직까지 개발되지 않은 현재, 당연히 COVID-19의 바이러스감염 또는 백신접종의 부작용 후유증으로 인해 발생하는 근감소증의 치료제는 존재하지 않는다.Currently, a treatment for sarcopenia caused by aging has not yet been developed. Naturally , there is no treatment for sarcopenia caused by the side effects of COVID-19 viral infection or vaccination .
따라서 근육 생성과 유지를 위해 충분한 양의 단백질을 섭취하고, 운동을 꾸준히 하는 것이 현재 최선의 치료법이자 예방법으로 사용되고 있다.Therefore, consuming sufficient amounts of protein and exercising consistently to build and maintain muscle is currently used as the best treatment and prevention method.
건강한 일반 노인 기준 일일 단백질 권장섭취량은 1kg당 0.8~1.2kg이다. 60kg의 성인이라면, 하루에 60g의 단백질을 섭취해야 한다. 근감소증 확진 판정을 받았다면, 이보다 더 많은 양의 단백질을 섭취해야 한다. 근감소증 환자는 체중 1kg당 1.2g의 단백질을 섭취해야 한다. 단백질 결핍이 심한 근감소증 환자라면 일일 1.5g까지도 섭취가 권고된다.The recommended daily protein intake for the general healthy elderly person is 0.8 to 1.2 kg per kg. An adult weighing 60 kg should consume 60 g of protein per day. If you have been diagnosed with sarcopenia, you need to consume more protein than this. Patients with sarcopenia should consume 1.2g of protein per kg of body weight. For sarcopenic patients with severe protein deficiency, it is recommended to consume up to 1.5g per day.
최근에 연구자들은 COVID-19 바이러스나 RNA백신항체가 어떤 원인으로 인해 세포(細胞)내(內)로 침투하면, 미토콘드리아를 파괴하여 용해시키고 그 결과 감염된 세포를 자멸하게 하는 사실을 발견하였다. [비특허문헌1]Recently, researchers discovered that when the COVID-19 virus or RNA vaccine antibodies penetrate into cells for some reason , they destroy and dissolve mitochondria, causing the infected cells to self-destruct . [Non-patent Document 1]
상기한 발견의 의미는 COVID-19의 감염 또는 백신접종의 부작용 후유증으로 인해 근감소증이 발생하는 주(主)된 원인이 전신적으로 거의 일시에 엄청나게 많은 수량의 COVID-19 바이러스나 RNA백신항체에 감염된 세포들이 자멸하되 그후에도 지속적으로 자멸하기 때문이다라는 것이다.The significance of the above findings is that the main cause of sarcopenia due to side effects of COVID-19 infection or vaccination is systemic infection with an extremely large amount of COVID-19 virus or RNA vaccine antibodies at almost the same time. This is because the cells self-destruct and then continue to self-destruct .
COVID-19의 감염 또는 백신접종의 부작용 후유증으로 발생하는 근감소증을 좀더 세밀히 들여다 보면, 그 발생의 주(主)된 원인이 일방(一方)으로는 전신(全身)적으로 거의 일시에 엄청나게 많은 수량(數量)의 COVID-19 바이러스나 RNA백신항체의 스파이크단백에 감염된 세포( 이후 '감염세포' 라고 한다)들이 지속적으로 자멸(自滅)하고 있다는 것과[비특허문헌1], 다른 일방(一方)으로는 전신적으로 생산되고 있는 줄기세포들로 부터 태어나는 새끼세포(이후 '새끼세포' 라고 한다)들이 자멸(自滅)되는 감염세포의 수량(數量)에 비하여 상대적으로 그 수량(數量)이 아주 적고 또 성장(成長) 중에 있어 정상세포와 비교할 때 그 크기가 상대적으로 아주 작다는 것과, 양방(兩方)의 결과로써 자멸하는 감염세포군과 이를 보충(補充)하는 새끼세포군간에 발생하는 생리적(生理的) 격차(隔差)현상(: 생리적 시간지연(;time lag))인 근육의 위축때문인 것이다. If we look more closely at sarcopenia that occurs as a side effect of COVID-19 infection or vaccination , the main cause of its occurrence is a huge amount of damage to the entire body, almost at once. On the other hand , cells (hereinafter referred to as 'infected cells') infected with the spike protein of the COVID-19 virus or RNA vaccine antibody are continuously self-destructing [Non-patent Document 1]. The number of baby cells (hereinafter referred to as ‘baby cells’) born from stem cells produced systemically is relatively small compared to the number of infected cells that self-destruct. Their size is relatively very small compared to normal cells during growth, and the physiological effect that occurs between the group of infected cells that self-destruct and the group of young cells that replenish them as a result of the two-way interaction This is due to muscle atrophy , which is a gap phenomenon (physiological time lag) .
따라서, 근감소증을 치료하기 위해서는 자멸하는 감염세포군의 자멸속도를 늦추는 것(: 근감소를 저지하고 개선하는 것)과 생산되는 새끼세포군의 수효를 확대하고 그 성장 속도를 인상(引上;boosting)하는 것( ; 근력을 유지하고 강화하는 것)으로 이루어지는 것이 치료특징인 치료메카니즘이 필수적이다.Therefore, in order to treat sarcopenia , it is necessary to slow down the rate of self-destruction of the infected cell population (blocking and improving muscle loss) and expanding the number of young cell populations produced and increasing their growth rate. It is essential to have a treatment mechanism that is characterized by treatment (maintaining and strengthening muscle strength) .
근감소증의 치료 시점(始點)에서 자멸하는 감염세포군의 자멸속도를 늦추는 것은 근육(筋肉)감소를 저지하고 개선하는 것이며, 근감소증의 치료 도중(途中)에서 생산되는 새끼세포군의 수효를 확대하고 그 성장 속도를 인상(引上,boosting)하는 것은 근력(筋力)을 유지하고 강화하는 것이다. Slowing down the rate of self-destruction of the infected cell group that self-destructs at the beginning of the treatment of sarcopenia prevents and improves muscle loss , and increases the number of new cell groups produced during the treatment of sarcopenia. Enlarging and boosting the rate of growth is all about maintaining and strengthening strength.
미토콘드리아가 손상되어 있는 감염세포군은 운동을 하면 할수록 더 빨리 자멸하여 소멸된다. 그 당연한 결과로서 근감소증이 악화된다. The more an infected cell group with damaged mitochondria undergoes self-destruction, the faster it disappears. As a natural result , sarcopenia worsens.
따라서 근감소증의 치료 초기(初期)에는 운동을 멈춰야 하며, 섭취하는 식품만으로 근육(筋肉)의 감소를 저지하고 개선해야 하는 것이다. 또 근력(筋力)을 유지하고 강화하는 식품의 섭취를 통하여 생산되는 새끼세포군의 수효를 확대하고 그 성장 속도를 인상(引上,boosting)하는 것이 필수적이다.Therefore, exercise should be stopped in the early stages of treatment for sarcopenia, and muscle loss should be prevented and improved only with the food consumed. In addition, it is essential to expand the number of young cells produced and boost their growth rate through the intake of foods that maintain and strengthen muscle strength.
따라서 근육(筋肉)의 감소를 저지하고 개선하는 목적의 식품의 제조와, 또한 근력(筋力)을 유지하고 강화하는 목적의 식품의 제조가 요구된다.[비특허문헌2]Therefore, there is a need to manufacture foods for the purpose of preventing and improving muscle loss, as well as for maintaining and strengthening muscle strength. [Non-patent Document 2]
본인은 세포차원에서 COVID-19 바이러스나 RNA백신항체의 스파이크단백에 감염되어 미토콘드리아가 손상된 세포( 이후 '감염세포' 라고 한다)들의 자멸을 저지하여 수명을 연장시키는 - 전신적 차원에서 근육감소를 저지하고 개선하는 - 특징이 있고, 줄기세포로부터 태어나는 딸세포( 이후 '새끼세포' 라고 한다)와, 딸-딸세포들의 생산을 증진하고 그 성장 속도를 인상(引上,boosting)하여 감염세포의 자멸을 적절한 속도로 보충하도록 하는 - 전신적 차원에서 근력(筋力)을 유지(維持)하고 강화(强化)시키는 - 특징이 있는 근감소증을 치료할 수 있는 치료메카니즘(치료원리)를 발견하였고, 동 발견에 기초하여, 동 치료메카니즘에 적합하고 적용가능한 COVID-19의 감염 또는 백신접종의 부작용 후유증으로 발생하는 근감소증을 저지하고 개선하는 식품제조방법을 발명한 것이다.I propose to prevent self-destruction of cells with damaged mitochondria (hereinafter referred to as 'infected cells') at the cellular level by being infected with the spike protein of the COVID-19 virus or RNA vaccine antibody, thus prolonging the lifespan - preventing muscle loss at the systemic level It has the characteristic of improving the production of daughter cells (hereinafter referred to as 'baby cells') born from stem cells , and the production of daughter cells and boosting their growth rate to appropriately suppress self-destruction of infected cells. A therapeutic mechanism (treatment principle) that can treat sarcopenia, which is characterized by maintaining and strengthening muscle strength at a systemic level, was discovered and based on this discovery, We have invented a food manufacturing method that prevents and improves sarcopenia that occurs as a side effect of COVID-19 infection or vaccination that is suitable and applicable to this treatment mechanism.
본 발명의 식품제조방법의 특징은 COVID-19 바이러스나 RNA백신항체의 부작용 후유증으로 발생한 감염세포군의 자멸을 저지하고 그 수명의 연장을 도모함으로써 근(筋)감소를 저지(沮止)하고 개선(改善)시키기 위한 목적으로 식품재료로 비타민D가 풍부한 버섯류가루와 칼슘과 단백질이 풍부한 멸치가루와 치즈분말, 찐계란가루와 비타민C를 사용하며, 생산되는 새끼세포군의 수효를 확대하고 그 성장 속도를 인상(引上;boosting)하는 것을 도모함으로써 근력을 유지하고 강화시키는 것을 목적으로 식품재료로 비타민D가 풍부한 버섯류가루와 칼슘과 단백질이 풍부한 멸치가루와 치즈분말, 찐계란가루, 유청분말과 대두분말을 사용하며, 먹기와 소화흡수를 용이하게 하기 위한 목적으로 식품재료로 우유와 두유( 이후 '발효베이스' 라고 한다)를 사용하는 특징이 있고, 상기한 식품재료들을 발효베이스에서 혼합한 식품재료( 이후 '혼합식품재료' 라고 한다)의 단백질을 아미노산으로 분해할 목적으로 식품재료로 단백질천연분해효소(:단백질을 아미노산들로 분해하는 천연효소)인 파인애플, 참다래, 배를 사용하며, 동 혼합식품재료의 당류를 분해할 목적으로 식품재료로 혼합유산균(; 당을 젖산과 기타 발효(醱酵)후(後)물질을 생산하는 여러 종류의 유산균주로 구성되는 혼합균주)인 김치유산균(: 김치를 우유베이스에서 발효하여 채집한 혼합유산균주)과 된장유산균(; 된장을 우유베이스에서 발효하여 채집한 혼합유산균주)을 사용한다. The characteristics of the food manufacturing method of the present invention are to prevent muscle loss and improve muscle loss by preventing self-destruction of infected cell populations that occur as a side effect of the COVID-19 virus or RNA vaccine antibodies and prolonging their lifespan ( For the purpose of reform, mushroom powder rich in vitamin D, anchovy powder and cheese powder rich in calcium and protein, steamed egg powder, and vitamin C are used as food ingredients to expand the number of young cell groups produced and increase their growth rate. For the purpose of maintaining and strengthening muscle strength by promoting boosting, mushroom powder rich in vitamin D, anchovy powder and cheese powder rich in calcium and protein, steamed egg powder, whey powder, and soybean powder are used as food ingredients. It has the characteristic of using milk and soy milk (hereinafter referred to as 'fermented base') as food ingredients for the purpose of facilitating eating, digestion and absorption , and food ingredients (hereinafter referred to as 'fermented base') mixed with the above-mentioned food ingredients in a fermented base. For the purpose of breaking down protein into amino acids , natural proteolytic enzymes (natural enzymes that break down proteins into amino acids) such as pineapple, tuna, and pear are used as food ingredients . Kimchi lactic acid bacteria (mixed lactic acid bacteria consisting of several types of lactic acid bacteria that produce lactic acid and other post-fermentation substances) used as food ingredients for the purpose of decomposing sugars, make kimchi as a milk base. Mixed lactic acid bacteria (mixed lactic acid bacteria collected by fermenting soybean paste in a milk base) and soybean paste lactic acid bacteria (mixed lactic acid bacteria collected by fermenting soybean paste in a milk base) are used.
본 발명은 COVID-19의 감염 또는 동백신접종의 부작용 후유증으로 발생하는 근육감소를 저지하고 개선하며, 근력(筋力)을 유지(維持)하고 강화(强化)시키는 목적이 특징인 치료메카니즘에 의거하여, 그 치료에 적용 가능한 상기한 식품재료들을 함유한 '혼합식품재료' 를 사용하는 것을 특징으로 하며, 동 '혼합식품재료' 를 단백질천연분해효소(:단백질을 아미노산들로 분해하는 천연효소)와 및 혼합유산균(; 당을 젖산과 기타 발효(醱酵)후(後)물질을 생산하는 여러 종류의 유산균의 혼합균주)으로 발효하여 제조하는 것이 그 특징인 근감소증을 저지하고 개선하는 식품제조법에 관한 것이다. The present invention is based on a treatment mechanism characterized by the purpose of preventing and improving muscle loss that occurs as a side effect of COVID-19 infection or vaccination, and maintaining and strengthening muscle strength. , It is characterized by using 'mixed food ingredients' containing the above-mentioned food ingredients applicable to the treatment, and the 'mixed food ingredients' are combined with proteolytic enzymes (natural enzymes that break down proteins into amino acids). and a food manufacturing method that prevents and improves sarcopenia, which is characterized by fermenting sugar with mixed lactic acid bacteria (a mixed strain of various types of lactic acid bacteria that produce lactic acid and other post-fermentation substances). It's about.
본 발명은 COVID-19감염 또는 동백신접종의 부작용 후유증으로 인하여 다수(多數) 세포 군(群)의 미토콘드리아의 손상(損傷)으로 발생한 근감소증의 치료는 물론이고 상기의 동일한 치료원리가 적용될 수 있는 근감소증의 치료에도 사용할 수 있다.The present invention is a treatment for sarcopenia caused by damage to mitochondria of a large number of cells due to side effects of COVID-19 infection or vaccination, as well as the same treatment principle as above. It can also be used to treat sarcopenia.
본 발명인은 본 발명의 방법으로 제조한 식품을 섭취하여, COVID-19 감염과 3차 모더나 백신접종의 부작용 후유증으로 발생한 본인의 근감소증에서 완치되었다. The present inventor was cured of his sarcopenia caused by COVID-19 infection and side effects of the third Moderna vaccination by consuming the food prepared by the method of the present invention.
본 발명을 상세히 설명하면 다음과 같다.The present invention will be described in detail as follows.
근(筋)감소를 저지(沮止)하고 개선(改善)시키기 위한 목적의 식품재료로 비타민D가 풍부한 버섯류가루와 칼슘과 단백질이 풍부한 멸치가루와 치즈분말, 찐계란가루와 비타민C를 1차로 혼합하여 1차 혼합물을 제조하되, 그 식품재료들의 무게 혼합비율을 버섯류가루: 멸치가루: 치즈분말: 찐계란가루 : 비타민C =( 2 내지 5) : (10 내지 30) : (10 내지 20) : (45 내지 120) : ( 1 내지 3)으로 한다.As a food ingredient for the purpose of preventing and improving muscle loss, it is first mixed with mushroom powder rich in vitamin D, anchovy powder rich in calcium and protein, cheese powder, steamed egg powder, and vitamin C. To prepare the first mixture, the weight mixing ratio of the food ingredients is mushroom powder: anchovy powder: cheese powder: steamed egg powder: vitamin C = (2 to 5) : (10 to 30) : (10 to 20) : ( 45 to 120): (1 to 3).
근력(筋力)을 유지하고 강화시키기 위한 목적으로 식품재료로 비타민D가 풍부한 버섯류가루와 칼슘과 단백질이 풍부한 멸치가루와 치즈분말, 찐계란가루, 유청분말과 대두분말을 2차로 혼합하여 2차 혼합물을 제조하되, 그 식품재료들의 무게 혼합비율을 버섯류가루: 멸치가루: 치즈분말: 찐계란가루 : 유청분말 : 대두 분말 = ( 2 내지 5) : (10 내지 30) : (10 내지 20) : (45 내지 120) : ( 5 내지 50) : ( 5 내지 50)으로 한다.For the purpose of maintaining and strengthening muscle strength, mushroom powder rich in vitamin D, anchovy powder rich in calcium and protein, cheese powder, steamed egg powder, whey powder, and soybean powder are mixed as food ingredients to create a secondary mixture. Manufactured, the weight mixing ratio of the food ingredients is mushroom powder: anchovy powder: cheese powder: steamed egg powder: whey powder: soybean powder = (2 to 5): (10 to 30): (10 to 20): (45 to 45) 120) : ( 5 to 50) : ( 5 to 50).
2차 혼합물의 제조시, 1차 혼합물의 식품재료와 겹쳐지는 식품재료들은 근감소증의 진행정도에 따라서 생략하여 혼합비율을 조정할 수 있다.When preparing the second mixture, food ingredients that overlap with the food ingredients of the first mixture can be omitted depending on the progress of sarcopenia and the mixing ratio can be adjusted.
먹기와 소화흡수를 용이하게 하기 위한 목적으로 식품재료로 우유와 두유와 상기(上記)한 1차 혼합물을 혼합한 3차 혼합물을 제조하되, 그 식품재료들의 무게 혼합비율을 우유 : 두유 : 버섯류가루 : 멸치가루 : 치즈분말 : 찐계란가루 : 비타민C = ( 100 내지 1000): ( 100 내지 1000): ( 2 내지 5) : (10 내지 30) : (10 내지 20) : (45 내지 120) : ( 1 내지 3) 으로 한다.In order to facilitate eating, digestion and absorption, a tertiary mixture is prepared by mixing milk, soy milk and the above-mentioned primary mixture as food ingredients, and the weight mixing ratio of the food ingredients is milk: soy milk: mushroom powder. : Anchovy powder: Cheese powder: Steamed egg powder: Vitamin C = (100 to 1000): (100 to 1000): (2 to 5): (10 to 30): (10 to 20): (45 to 120): ( 1 to 3).
단백질을 아미노산으로 분해할 목적으로 한 식품재료인 단백질천연분해효소인 파인애플, 참다래, 배와 또 당을 발효하여 젖산과 기타 발효(醱酵)후(後)물질을 생산할 목적으로한 식품재료인 김치-혼합유산균발효요구르트와 된장-혼합유산균발효요구르트를 상기한 3차 혼합물에 혼합하여 4차 혼합물을 제조하되. 그 식품 재료들의 무게 혼합비율을 파인애플 : 참다래 : 배 : 김치혼합유산균 요구르트 : 된장혼합유산균 요구르트 : 우유 : 두유 : 버섯류가루 : 멸치가루 : 치즈분말 : 찐계란가루 : 비타민C = ( 30 내지 200) : ( 30 내지 200) : ( 30 내지 200) : ( 50 내지 150) : ( 50 내지 150) : ( 100 내지 1000): ( 100 내지 1000): ( 2 내지 5) : (10 내지 30) : (10 내지 20) : (45 내지 120) : ( 1 내지 3) 으로 한다. Pineapple, persimmon, and pear, which are food ingredients with natural protein decomposition enzymes that are intended to break down proteins into amino acids, and kimchi, which is a food ingredient that is intended to produce lactic acid and other post-fermentation substances by fermenting sugars. -Mixed lactic acid bacteria fermented yogurt and soybean paste-mixed lactic acid bacteria fermented yogurt are mixed with the above-mentioned 3rd mixture to prepare the 4th mixture. The weight mixing ratio of the food ingredients is as follows: pineapple: persimmon: pear: kimchi mixed lactic acid bacteria yogurt: soybean paste mixed lactic acid bacteria yogurt: milk: soy milk: mushroom powder: anchovy powder: cheese powder: steamed egg powder: Vitamin C = (30 to 200): ( 30 to 200) : ( 30 to 200) : ( 50 to 150) : ( 50 to 150) : ( 100 to 1000): ( 100 to 1000): ( 2 to 5) : (10 to 30) : (10 to 20): (45 to 120): (1 to 3).
상기한 4차 혼합물에 2차 혼합물을 혼합하여 5차 혼합물을 제조한다.The fifth mixture is prepared by mixing the second mixture with the fourth mixture described above.
상기한 5차 혼합물을 상온에서 24시간 내지 72 시간동안 유산균 발효한 식품으로 제조하는 것이 그 특징인 COVID-19의 감염 또는 백신접종의 부작용 후유증으로 발생하는 근감소증을 개선하는 식품제조법이다.It is a food manufacturing method that improves sarcopenia that occurs as a side effect of COVID-19 infection or vaccination, characterized by manufacturing the above-mentioned 5th mixture into food that is fermented with lactic acid bacteria for 24 to 72 hours at room temperature.
[실시예][Example]
본인은 3차 모더나 백신접종후 동(同) 백신 부작용과 2차례의 COVID-19 감염의 후유증으로 근감소증이 발병하여 고통을 겪었지만 효과적인 의학적인 치료법을 찾을 수 없었다. After receiving the third Moderna vaccine, I suffered from sarcopenia due to side effects from the same vaccine and the aftereffects of two COVID-19 infections, but I was unable to find an effective medical treatment.
근감소증으로 위기를 맞은 본인은 RNA백신부작용과 2차례의 COVID-19 감염의 부작용 후유증으로 발병한 근감소증을 연구할 수 밖에 없었고, 그 결과 상기한 치료메카니즘을 발견할 수 있었으며, 그 후에 상기한 치료원리에 적합한 COVID-19의 감염 또는 백신접종의 부작용 후유증으로 발생하는 근감소증을 개선하는 식품제조법을 발명하게 된 것이다. Faced with a crisis due to sarcopenia, I had no choice but to research sarcopenia, which developed as a side effect of the RNA vaccine and the side effects of two COVID-19 infections. As a result, I was able to discover the above-mentioned treatment mechanism, and after that, the above-mentioned treatment mechanism was discovered. We have invented a food manufacturing method that improves sarcopenia that occurs as a side effect of COVID-19 infection or vaccination, which is suitable for treatment principles.
본인은 본 발명의 제조방법으로, 5차 혼합물의 식품재료들의 무게 비율을 파인애플 : 참다래 : 배 : 김치혼합유산균 요구르트 : 된장혼합유산균 요구르트 : 우유 : 두유 : 표고버섯가루 : 멸치가루 : 치즈분말 : 찐계란가루 : 비타민C = ( 30 ) : ( 100) : ( 30 ) : ( 50 ) : ( 50 ) : ( 500): ( 500): ( 5 ) : (20) : (20 ) : (100) :( 2) 으로 한 식품을 제조하여 매회 250g을 하루에 3번 1개월간 섭취하여, 1.5개월 만에 82kg에서 72kg으로 감소했던 체중이 75kg으로 회복되었고, 커피컵도 들기 힘들던 손으로 4kg아령을 12회씩 3회 연속해서 들 수 있게 되었고, 걷기도 힘들던 상태에서 300m 이상 구보와 4Km 이상의 보행도 가능하게 되었고, 한 계단도 오르기 내리기 힘들던 상태에서 20 계단 이상을 반복해서 오르내릴 수 있게 되었고, 앉았던 변기의자에서 일어나기도 힘들던 상태에서 쉽게 일어날 수 있게 되었다.By using the manufacturing method of the present invention, the weight ratio of the food ingredients of the 5th mixture was pineapple : kiwifruit: pear: kimchi mixed lactic acid bacteria yogurt: soybean paste mixed lactic acid bacteria yogurt: milk: soy milk: shiitake mushroom powder: anchovy powder: cheese powder: steamed egg. Powder: Vitamin C = ( 30 ) : ( 100) : ( 30 ) : ( 50 ) : ( 50 ) : ( 500): ( 500): ( 5 ) : (20) : (20 ) : (100) :( 2) By making a food and consuming 250g each time 3 times a day for 1 month, my weight, which had decreased from 82kg to 72kg in 1.5 months, recovered to 75kg, and I was able to lift 4kg dumbbells 12 times each with a hand that was difficult to even hold a coffee cup. I was able to lift the stairs several times in a row, I went from having difficulty walking to being able to walk more than 300m and walk more than 4km, I went from having difficulty going up and down even a single step to being able to climb up and down more than 20 steps repeatedly, and I was able to get up from the toilet chair I was sitting on. I was able to get up easily from difficult situations.
본인은 본 발명의 방법으로 제조한 식품을 지속적으로 섭취하며 근감소증의 위기에서 벗어나고 있는 중이다. I am escaping from the crisis of sarcopenia by continuously consuming foods prepared by the method of the present invention.
본 발명의 방법으로 제조한 식품은 COVID-19 감염 또는 동백신접종의 부작용 후유증으로 인하여 다수(多數) 세포 군(群)의 미토콘드리아의 손상(損傷)으로 발생한 근감소증의 치료는 물론이고 상기의 동일한 치료원리가 적용될 수 있는 근감소증의 치료에도 사용할 수 있다.The food manufactured by the method of the present invention is used for the treatment of sarcopenia caused by damage to mitochondria of a large number of cell groups due to side effects of COVID-19 infection or vaccination, as well as the same treatment as above. It can also be used to treat sarcopenia, where the treatment principle can be applied.
Claims (1)
근(筋)감소를 저지(沮止)하고 개선(改善)시키기 위한 목적의 식품재료로 비타민D가 풍부한 버섯류가루와 칼슘과 단백질이 풍부한 멸치가루와 치즈분말, 찐계란가루와 비타민C를 1차로 혼합하여 1차 혼합물을 제조하되, 그 식품재료들의 무게 혼합비율을 버섯류가루: 멸치가루: 치즈분말: 찐계란가루 : 비타민C =( 2 내지 5) : (10 내지 30) : (10 내지 20) : (45 내지 120) : ( 1 내지 3)으로 한다.
근력(筋力)을 유지하고 강화시키기 위한 목적으로 식품재료로 비타민D가 풍부한 버섯류가루와 칼슘과 단백질이 풍부한 멸치가루와 치즈분말, 찐계란가루, 유청분말과 대두분말을 2차로 혼합하여 2차 혼합물을 제조하되, 그 식품재료들의 무게 혼합비율을 버섯류가루: 멸치가루: 치즈분말: 찐계란가루 : 유청분말 : 대두 분말 = ( 2 내지 5) : (10 내지 30) : (10 내지 20) : (45 내지 120) : ( 5 내지 50) : ( 5 내지 50)으로 한다.
2차 혼합물의 제조시, 1차 혼합물의 식품재료와 겹쳐지는 식품재료들은 근감소증의 진행정도에 따라서 생략하여 혼합비율을 조정할 수 있다.
먹기와 소화흡수를 용이하게 하기 위한 목적으로 식품재료로 우유와 두유와 상기(上記)한 1차 혼합물을 혼합한 3차 혼합물을 제조하되, 그 식품재료들의 무게 혼합비율을 우유 : 두유 : 버섯류가루 : 멸치가루 : 치즈분말 : 찐계란가루 : 비타민C = ( 100 내지 1000): ( 100 내지 1000): ( 2 내지 5) : (10 내지 30) : (10 내지 20) : (45 내지 120) : ( 1 내지 3) 으로 한다.
단백질을 아미노산으로 분해할 목적으로 한 식품재료인 단백질천연분해효소인 파인애플, 참다래, 배와 또 당을 발효하여 젖산과 기타 발효(醱酵)후(後)물질을 생산할 목적으로한 식품재료인 김치-혼합유산균발효요구르트와 된장-혼합유산균발효요구르트를 상기한 3차 혼합물에 혼합하여 4차 혼합물을 제조하되. 그 식품 재료들의 무게 혼합비율을 파인애플 : 참다래 : 배 : 김치혼합유산균 요구르트 : 된장혼합유산균 요구르트 : 우유 : 두유 : 버섯류가루 : 멸치가루 : 치즈분말 : 찐계란가루 : 비타민C = ( 30 내지 200) : ( 30 내지 200) : ( 30 내지 200) : ( 50 내지 150) : ( 50 내지 150) : ( 100 내지 1000): ( 100 내지 1000): ( 2 내지 5) : (10 내지 30) : (10 내지 20) : (45 내지 120) : ( 1 내지 3) 으로 한다.
상기한 4차 혼합물에 2차 혼합물을 혼합하여 5차 혼합물을 제조한다.
상기한 5차 혼합물을 상온에서 24시간 내지 72 시간동안 유산균 발효한 식품으로 제조하는 것이 그 특징인 COVID-19의 감염 또는 백신접종의 부작용 후유증으로 발생하는 근감소증을 개선하는 식품제조법이다.The present invention relates to a food manufacturing method that improves sarcopenia that occurs as a side effect of COVID-19 infection or vaccination,
As a food ingredient for the purpose of preventing and improving muscle loss, it is first mixed with mushroom powder rich in vitamin D, anchovy powder rich in calcium and protein, cheese powder, steamed egg powder, and vitamin C. To prepare the first mixture, the weight mixing ratio of the food ingredients is mushroom powder: anchovy powder: cheese powder: steamed egg powder: vitamin C = (2 to 5) : (10 to 30) : (10 to 20) : ( 45 to 120): (1 to 3).
For the purpose of maintaining and strengthening muscle strength, mushroom powder rich in vitamin D, anchovy powder rich in calcium and protein, cheese powder, steamed egg powder, whey powder, and soybean powder are mixed as food ingredients to create a secondary mixture. Manufactured, the weight mixing ratio of the food ingredients is mushroom powder: anchovy powder: cheese powder: steamed egg powder: whey powder: soybean powder = (2 to 5): (10 to 30): (10 to 20): (45 to 45) 120) : ( 5 to 50) : ( 5 to 50).
When preparing the second mixture, food ingredients that overlap with the food ingredients of the first mixture can be omitted depending on the progress of sarcopenia and the mixing ratio can be adjusted.
In order to facilitate eating, digestion and absorption, a tertiary mixture is prepared by mixing milk, soy milk and the above-mentioned primary mixture as food ingredients, and the weight mixing ratio of the food ingredients is milk: soy milk: mushroom powder. : Anchovy powder: Cheese powder: Steamed egg powder: Vitamin C = (100 to 1000): (100 to 1000): (2 to 5): (10 to 30): (10 to 20): (45 to 120): ( 1 to 3).
Pineapple, persimmon, and pear, which are food ingredients with natural protein decomposition enzymes that are intended to break down proteins into amino acids, and kimchi, which is a food ingredient that is intended to produce lactic acid and other post-fermentation substances by fermenting sugars. -Mixed lactic acid bacteria fermented yogurt and soybean paste-mixed lactic acid bacteria fermented yogurt are mixed with the above-mentioned 3rd mixture to prepare the 4th mixture. The weight mixing ratio of the food ingredients is as follows: pineapple: persimmon: pear: kimchi mixed lactic acid bacteria yogurt: soybean paste mixed lactic acid bacteria yogurt: milk: soy milk: mushroom powder: anchovy powder: cheese powder: steamed egg powder: Vitamin C = (30 to 200): ( 30 to 200) : ( 30 to 200) : ( 50 to 150) : ( 50 to 150) : ( 100 to 1000): ( 100 to 1000): ( 2 to 5) : (10 to 30) : (10 to 20): (45 to 120): (1 to 3).
The fifth mixture is prepared by mixing the second mixture with the fourth mixture described above.
This is a food manufacturing method that improves sarcopenia that occurs as a side effect of COVID-19 infection or vaccination, characterized by manufacturing the above-mentioned 5th mixture into food that is fermented with lactic acid bacteria for 24 to 72 hours at room temperature.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020220182757A KR20240100778A (en) | 2022-12-23 | 2022-12-23 | Food manufacturing method to improve sarcopenia caused by infection with COVID-19 or as a side effect of vaccination |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020220182757A KR20240100778A (en) | 2022-12-23 | 2022-12-23 | Food manufacturing method to improve sarcopenia caused by infection with COVID-19 or as a side effect of vaccination |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20240100778A true KR20240100778A (en) | 2024-07-02 |
Family
ID=91933350
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020220182757A KR20240100778A (en) | 2022-12-23 | 2022-12-23 | Food manufacturing method to improve sarcopenia caused by infection with COVID-19 or as a side effect of vaccination |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20240100778A (en) |
-
2022
- 2022-12-23 KR KR1020220182757A patent/KR20240100778A/en unknown
Non-Patent Citations (4)
Title |
---|
[비특허문헌1] 4178. 질병의 치료원리; 코로나 감염 혈관질환, 스파이크단백질이 직접 일으킨다; ACE2 수용체 신호 교란, 혈관 내피세포의 미토콘드리아 파괴; 미국 소크 연구소, 미국 심장협회 저널에 논문; [ https://blog.naver.com/chkwkim/222335426094 ]. 2021. 5. 3.( 검색일 ; 2022.12.21.) |
[비특허문헌2] 112.약용 요구르트 제조법: 매일유업 사코페니아연구소, 근감소증 예방 소재 발견…"국제 학술지 게재"; 정세영 경희대 교수팀 공동 연구…'유청단백가수분해물' 효능 입증; [ https://blog.naver.com/chkwkim/222275148710 ]. 2021. 3. 14.( 검색일 ; 2022.12.21.) <;연구진은 근육이 위축된 쥐에 유청단백가수분해물(WPH)을 투여해 변화를 추적했다. 유청단백가수분해물을 섭취한 쥐는 대조군과 비교해 △근력 14.6% △대퇴사두근 12.8% △장딴지근 16.3% △가자미근 41.6% △근섬유 단면적 64.8%가 증가하는 결과를 보였다. 특히 근감소율은 줄이고 근합성율은 높이는 데 영향을 미치는 것을 확인했다. -- 근육이 위축된 5주령 쥐에 유청단백가수분해물을 투여해 근육량과 근력 및 근섬유 단면적이 뚜렷하게 증가한 실험 결과(매일유업 제공)ⓒ 뉴스1> |
[비특허문헌3] 1232. 치유음식 2 ; '이 영양소' 부족한 노인, 근육 감소 위험 높아; 비타민D가 결핍된 노인들은 근력 감소 위험이 높다는 연구결과가 나왔다; [ https://blog.naver.com/chkwkim/222956704588 ]. 2022. 12. 15(검색일자 2022,12,21.) <;근력을 강화하려면 꾸준한 운동과 함께 음식·영양제 등을 통해 '비타민D' 를 보충할 필요가 있다. 칼슘 흡수를 돕는 비타민D는 근력 유지·강화를 위해 반드시 필요한 영양소로, 고기, 생선, 버섯, 달걀, 치즈, 우유 등에 많이 들어있다. 비타민D 수치를 높이기 위해서는 평소 햇볕을 자주 쬐는 것 또한 중요하다.> |
[비특허문헌4] 1483. 기타 만성질환의 예방과 치유; 평소 '이 속도' 느려졌다면… 근감소증 의심; ◇잘 못 걷는 근감소증, 합병증 위험 커/근감소증은 노화로 근력이 감소해 생긴다;[ https://blog.naver.com/chkwkim/222931406327]. 2022. 11. 18.(검색일자 2022,12,21.) |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2239784T3 (en) | PHARMACOS ATIESTRES AND FUNCTIONAL FOODS CONTAINING ANCIENT EFFECTS. | |
CN105167072A (en) | Production method of functional Chinese wolfberry fruit enzyme and product thereof | |
CN103431390B (en) | Lycium ruthenicum eyesight improving preparation | |
CN105641209A (en) | Probiotics composition with function of improving immunity and preparing method and application of probiotics composition | |
JP4231208B2 (en) | Nutritional supplements derived from fermented milk for the prevention of osteoporosis | |
CN103211150A (en) | Polypeptide food containing active earthworm protein | |
CN104232441A (en) | Health caring and preserving cordyceps wine and preparation method thereof | |
CN103190483A (en) | Children growth promotion milk tea | |
CN107549309B (en) | Fruity selenium-rich cordyceps militaris yoghourt product and preparation method thereof | |
JP2023515275A (en) | Composition for treating menopausal disease containing Lactobacillus gasseri BNR17 | |
CN105661547A (en) | Probiotics and Bombyx mori compounded diabetic patient nutritional supplement | |
KR20120021349A (en) | Functional food and pharmaceutical composition for treatment and prevention of diabetes using yerusalem artichoke fermented by lactic acid bacteria | |
CN110313599A (en) | A kind of anti-trioxypurine jelly and preparation method thereof | |
KR101935848B1 (en) | Food composition for improving hyperglycemia using Brassica rapa | |
CN102273581A (en) | Compound sweetener with high sweetness | |
KR20240100778A (en) | Food manufacturing method to improve sarcopenia caused by infection with COVID-19 or as a side effect of vaccination | |
JP2005312424A (en) | Method for producing fermented product using kefir grain, and fermented product obtained by the same | |
CN104082656B (en) | Nutrient meal suitable for patient with liver disease and manufacturing method thereof | |
CN103719864A (en) | Blood glucose-reducing natto combined capsule and preparation method thereof | |
CN109965072A (en) | A kind of pressed candy and the preparation method and application thereof conserving liver | |
KR20020069239A (en) | Mucosal immunomodulator and use thereof | |
CN110384240A (en) | Hypoglycemic vitamin and probiotics fermention object powder alimentation composition and its application | |
CN108124793A (en) | Improve the cultural method of Tilapia quality | |
CN102511882A (en) | Red jujube thick syrup beneficial for improving growth and development | |
CN107362245A (en) | It is a kind of that there is the anti-oxidant and composition of reducing homosysteine |